Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 36.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,346 shares of the company’s stock after purchasing an additional 11,870 shares during the period. Natixis Advisors LLC owned 0.06% of Crinetics Pharmaceuticals worth $2,266,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in CRNX. Comerica Bank purchased a new stake in Crinetics Pharmaceuticals during the 1st quarter valued at about $33,000. Quest Partners LLC acquired a new position in Crinetics Pharmaceuticals in the second quarter valued at approximately $42,000. Values First Advisors Inc. purchased a new position in Crinetics Pharmaceuticals in the third quarter worth approximately $84,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the 3rd quarter worth about $91,000. Finally, KBC Group NV increased its position in shares of Crinetics Pharmaceuticals by 22.8% during the third quarter. KBC Group NV now owns 2,193 shares of the company’s stock valued at $112,000 after acquiring an additional 407 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company’s stock.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 1,035 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $51.50, for a total value of $53,302.50. Following the completion of the sale, the insider now owns 68,576 shares in the company, valued at approximately $3,531,664. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Marc Wilson sold 25,000 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $51.11, for a total transaction of $1,277,750.00. Following the completion of the transaction, the chief financial officer now directly owns 111,092 shares in the company, valued at $5,677,912.12. The trade was a 18.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,410 shares of company stock worth $2,116,359 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on CRNX. HC Wainwright increased their target price on Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Citigroup increased their price target on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and issued a $80.00 price objective on shares of Crinetics Pharmaceuticals in a report on Friday, September 27th. Oppenheimer reiterated an “outperform” rating and set a $73.00 target price (down from $74.00) on shares of Crinetics Pharmaceuticals in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $90.00 price target on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $70.18.

Crinetics Pharmaceuticals Stock Down 1.7 %

Shares of CRNX opened at $56.06 on Monday. The company has a market capitalization of $5.20 billion, a price-to-earnings ratio of -15.03 and a beta of 0.62. Crinetics Pharmaceuticals, Inc. has a 52-week low of $30.50 and a 52-week high of $62.53. The stock has a 50 day moving average price of $55.36 and a 200 day moving average price of $51.60.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same quarter last year, the business posted ($1.01) EPS. On average, equities analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.75 EPS for the current fiscal year.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.